Answers are grounded in this paper and cite their sources.
In our study, up to 50% of myeloma patients on long-term lenalidomide therapy developed sensory axonal neuropathy. Reduced dorsal sural nerve sensory action potential amplitude was the first neurophysiologic alteration. Neuropathy was usually subclinical or mild, however. Neurotoxicity was independent of lenalidomide cumulative dose and hematologic response.
No takes yet. Share an insight, caveat, or question.
Torre et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: